Please fill out the pre-assessment below before the session begins.

1. Think of a patient with chronic-phase CML who has failed multiple TKIs and is found to have a BCR-ABL1 T315I mutation. The patient has well-controlled hypertension and no history of vascular disease. According to long-term follow-up from the PACE trial, which ponatinib dosing strategy is most appropriate to initiate therapy while balancing efficacy and vascular risk?
2. When initiating therapy for a patient with chronic-phase CML, which of the following is the most important factor to consider in selecting a tyrosine kinase inhibitor
3. In CML, aside from BCR::ABL1, which of the following has a validated therapeutic target with proven clinical benefit in predicting treatment response or guiding therapy?
Scroll to Top